Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Human Tissue Distribution of Voriconazole

Stefan Weiler, David Fiegl, Róisín MacFarland, Eva Stienecke, Rosa Bellmann-Weiler, Stefan Dunzendorfer, Michael Joannidis, Romuald Bellmann
Stefan Weiler
1Clinical Pharmacokinetics Unit, Inflammation Research Laboratory, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Fiegl
1Clinical Pharmacokinetics Unit, Inflammation Research Laboratory, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Róisín MacFarland
1Clinical Pharmacokinetics Unit, Inflammation Research Laboratory, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Stienecke
1Clinical Pharmacokinetics Unit, Inflammation Research Laboratory, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Bellmann-Weiler
2Clinical Immunology and Infectious Diseases, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Dunzendorfer
3Medical Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Joannidis
3Medical Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romuald Bellmann
1Clinical Pharmacokinetics Unit, Inflammation Research Laboratory, Innsbruck Medical University, Innsbruck, Austria
3Medical Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: romuald.bellmann@i-med.ac.at
DOI: 10.1128/AAC.00949-10
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Voriconazole concentrations were determined in autopsy samples of eight patients who had been treated for a median of 7 days (interquartile range [IQR], 5 days). Voriconazole penetrates well into various tissues, with median levels of 6.26 μg/g ((interquartile range [IQR], 7.87 μg/g) in the lung, 3.41 μg/g (IQR, 16.72 μg/g) in the brain, 6.89 μg/g (IQR, 24.16 μg/g) in the liver, 6.47 μg/g (IQR, 6.19 μg/g) in the kidneys, 5.60 μg/g (IQR, 11.49 μg/g) in the spleen, and 7.55 μg/g (IQR, 16.91 μg/g) in the myocardium.

Voriconazole (VRC) is an expanded-spectrum triazole with a broad antimycotic spectrum, including Aspergillus and non-albicans Candida species. It is the drug of choice for treatment of invasive aspergillosis (12, 27). The bioavailability after oral intake of VRC is reported to be almost complete (96%) in healthy volunteers, but lower and variable in patients (23.7 to 63.3%) (11). Since data on VRC distribution into human tissues have been sparse so far, we determined concentrations in autopsy samples.

The study was approved by the local ethics committee. Consent was granted by the patients' relatives. Tissue samples were obtained during routine autopsy from eight patients who had died at the medical intensive care unit (ICU) during VRC treatment. The patients' characteristics and data on VRC therapy are displayed in Table 1; routine laboratory values are shown in Table 2.

VRC (Vfend; Pfizer) had been administered for possible, probable, or proven invasive aspergillosis intravenously (six patients) or as an oral suspension (two patients) at the standard dose. Aliquots (∼7 g) were taken from lung, brain, liver, spleen, kidneys, and myocardium and were stored at −80°C. After thawing, samples were homogenized (Ultraturrax T25; Germany) and purified by C18 solid-phase extraction. VRC was quantified by the high-performance liquid chromatography method by Khoschsorur et al. (14), with some modifications, using a Zorbax 300SB-C18 analytical column, UV detection (λ = 255 nm), and a mixture of sodium dihydrogen phosphate buffer, acetonitrile, and methanol (35:45:20 [vol/vol]) as the mobile phase. The detection limit was 0.25 μg/g. The intraday precision, interday precision, and accuracy (mean ± standard deviation) were 4.2% ± 3.7%, 8.8% ± 5.2%, and 7.4% ± 9.6%, respectively. The concentrations were assessed by means of a linear standard curve (R = 0.999), obtained by external standards comprising respective bovine tissues spiked with VRC. The mean VRC recovery was 80%.

Table 3 displays the VRC concentrations in the different tissue samples. VRC was shown to penetrate well into tissues, with high variability. In patient 1, VRC was detectable even after a low single dose in all tissues but brain and myocardium. Tissue drug levels of all the other patients exceeded those achieved in patient 1. In patient 7 (daily dose of 600 mg for 6 days of VRC treatment), the highest concentrations were achieved in most tissue samples. He also exhibited the highest values in liver and renal function tests. No difference in VRC levels was found between different areas of the lung, nor were there discrepancies between cerebral cortex, hippocampus, nucleus caudatus, medulla oblongata, and cerebellum.

After multiple dosing, VRC levels in the liver correlated with the daily doses (R = 0.79, P = 0.03; in the other organs, R was between 0.38 and 0.64, P > 0.05), but not with the cumulative dose or the interval between the last administration and death. There was no significant difference in tissue concentrations between patients on and off renal replacement therapy. No signs of VRC toxicity could be observed (Table 2).

Invasive aspergillosis most frequently affects the respiratory tract and the central nervous system. The myocardium, the liver, and the spleen are further target organs of invasive fungal infections. We found mean VRC tissue concentrations that exceed therapeutic plasma levels (∼2.0 to 5.5 μg/ml) (19, 22) and the MICs for Aspergillus species (∼0.25 to 2 μg/ml) (15). However, the significance of in vivo target site concentrations in relation to in vitro MICs is controversial considering clinical efficacy.

The lack of therapeutic VRC monitoring precluded a comparison with plasma drug levels. The limited number of patients, differences in underlying diseases, including hepatic and renal function, as well as varying cumulative VRC doses and variable intervals between the last VRC administration and death of the patient are further limitations of our study. Agonal or postmortem changes in VRC tissue concentrations cannot be ruled out completely, although VRC was found to be stable in tissue at 4°C for at least 72 h. Between the tissue drug concentrations and death-to-sampling interval, no correlation was observed. Free VRC and protein-bound VRC were not separated by our assay. The tissue samples consisted of various compartments that are potential targets of fungal invasion, such as different cells, extracellular matrix, and blood vessels (18). However, with our method we could not study the VRC distribution on a cellular level.

In pulmonary epithelial lining fluid (ELF) of lung transplant recipients, VRC levels were between 0.3 and 83.3 μg/ml (3). In ELF of healthy volunteers, mean levels amounted to 10.1 to 48.3 μg/ml; in alveolar macrophages, mean levels were 10.3 to 20.6 μg/ml (5). Thus, the mean VRC concentration we found in lung tissue was somewhat lower than that in ELF. In vitro incubation of polymorphonuclear leukocytes with 2 μg/ml of VRC resulted in intracellular levels of ∼15 μg/ml (1). Relatively small amounts of VRC (0.7 to 4.4 μg/ml) were recovered from pleural fluid (17, 21, 23). VRC penetration into cerebrospinal fluid appears to be variable, yielding levels of 0.08 to 3.93 μg/ml (6, 16). Cerebral VRC concentrations had been determined previously in autopsy samples from two patients where 11.8 and 58.5 μg/g were measured and, thus, which exceed the levels we measured in our study population (16). In a brain abscess, 1.2 to 1.4 μg/g was reached by oral intake of 4 mg/kg twice daily (8). In contrast, none of our patients presented with cerebral mycosis. Studies of chickens and horses revealed remarkable interspecies differences in tissue penetration of VRC (2, 4, 20). In rats, free extracellular lung concentrations reached ∼2.5 μg/ml after a single dose (13).

Fluconazole, the ancestor drug of VRC, has been found to achieve high levels in various tissues, including the brain (25). In contrast, amphotericin B preparations accumulate in liver and spleen but achieve only low levels in brain and myocardium (26). Unlike with VRC, amphotericin B levels in lung tissue are much higher than in ELF (28). In comparison with amphotericin B, VRC therapy of invasive aspergillosis achieved a superior clinical outcome (12). Echinocandins displayed a tissue distribution similar to that of amphotericin B in animal studies (9, 10, 24).

In conclusion, treatment with VRC at standard doses yields concentrations above the MICs of relevant fungal pathogens in various frequently affected tissues. The significance of target site levels of antifungals for the clinical response should be addressed by adequately powered clinical trials.

View this table:
  • View inline
  • View popup
TABLE 1.

Demographic and clinical characteristics of patients

View this table:
  • View inline
  • View popup
TABLE 2.

Routine laboratory results for patients

View this table:
  • View inline
  • View popup
TABLE 3.

Voriconazole concentrations in 128 tissue samples from eight patients

ACKNOWLEDGMENTS

We are indebted to Gregor Mikuz, Andrea Brunner, Christian Ensinger, Jens Krugmann, Hans Maier, Patrizia Moser, Ralf Rieker, Consolato Sergi, Irmgard Verdorfer, and Bettina Zelger, Institute of Pathology, Innsbruck Medical University, for providing the tissue samples.

We thank Pfizer, Austria, for financial support.

FOOTNOTES

    • Received 13 July 2010.
    • Returned for modification 4 October 2010.
    • Accepted 7 November 2010.
    • Accepted manuscript posted online 15 November 2010.
  • Copyright © 2011, American Society for Microbiology

REFERENCES

  1. 1.↵
    Ballesta, S., I. Garcia, E. J. Perea, and A. Pascual. 2005. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 55:785-787.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Burhenne, J., W. E. Haefeli, M. Hess, and A. Scope. 2008. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. J. Avian Med. Surg. 22:199-207.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Capitano, B., et al. 2006. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50:1878-1880.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Colitz, C. M., et al. 2007. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses. Am. J. Vet. Res. 68:1115-1121.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Crandon, J. L., et al. 2009. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 53:5102-5107.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Denes, E., N. Pichon, M. Debette-Gratien, B. Bouteille, and J. M. Gaulier. 2004. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin. Infect. Dis. 39:603-604.
    OpenUrlCrossRefPubMed
  7. 7.
    De Pauw, B., et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Elter, T., et al. 2006. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int. J. Antimicrob. Agents 28:262-265.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Groll, A. H., et al. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45:2845-2855.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Groll, A. H., et al. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322-3327.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Han, K., et al. 2010. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:4424-4431.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Joukhadar, C., et al. 2009. Concentrations of voriconazole in healthy and inflamed lung in rats. Antimicrob. Agents Chemother. 53:2684-2686.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Khoschsorur, G., F. Fruehwirth, and S. Zelzer. 2005. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob. Agents Chemother. 49:3569-3571.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Lass-Florl, C., et al. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Lutsar, I., S. Roffey, and P. Troke. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37:728-732.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Matsuda, T., et al. 2010. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid. Intern. Med. 49:1163-1169.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Müller, M., A. dela Peña, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
    OpenUrlFREE Full Text
  19. 19.↵
    Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Passler, N. H., et al. 2010. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing. J. Vet. Pharmacol. Ther. 33:35-41.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Poupelin, J. C., et al. 2006. Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome. Intensive Care Med. 32:939-940.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Stern, J. B., P. Girard, and R. Caliandro. 2004. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis. Antimicrob. Agents Chemother. 48:1065.
    OpenUrlFREE Full Text
  24. 24.↵
    Stone, J. A., et al. 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother. 48:815-823.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    Thaler, F., et al. 1995. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob. Agents Chemother. 39:1154-1156.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    Vogelsinger, H., et al. 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother. 57:1153-1160.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Weiler, S., et al. 2009. Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. Antimicrob. Agents Chemother. 53:4934-4937.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Human Tissue Distribution of Voriconazole
Stefan Weiler, David Fiegl, Róisín MacFarland, Eva Stienecke, Rosa Bellmann-Weiler, Stefan Dunzendorfer, Michael Joannidis, Romuald Bellmann
Antimicrobial Agents and Chemotherapy Jan 2011, 55 (2) 925-928; DOI: 10.1128/AAC.00949-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Tissue Distribution of Voriconazole
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Human Tissue Distribution of Voriconazole
Stefan Weiler, David Fiegl, Róisín MacFarland, Eva Stienecke, Rosa Bellmann-Weiler, Stefan Dunzendorfer, Michael Joannidis, Romuald Bellmann
Antimicrobial Agents and Chemotherapy Jan 2011, 55 (2) 925-928; DOI: 10.1128/AAC.00949-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596